AZADIRACHTIN B


Synonyms	Azadirachtin B
UNII	X5T1RMZ28I
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	USRBWQQLHKQWAV-ZGKQVQOISA-N
Smiles	COC(=O)[C@H]1OC[C@@]23[C@@H](O)C[C@@H](OC(=O)\C(=C\C)\C)[C@]4(CO[C@@H]([C@@H](O)[C@](C)([C@H]12)[C@]56O[C@@]5(C)[C@H]7C[C@@H]6O[C@@H]8OC=C[C@]78O)[C@H]34)C(=O)OC
InChI	InChI=1S/C33H42O14/c1-7-14(2)24(36)45-17-11-16(34)30-12-44-20(25(37)40-5)21(30)28(3,23(35)19-22(30)31(17,13-43-19)26(38)41-6)33-18-10-15(29(33,4)47-33)32(39)8-9-42-27(32)46-18/h7-9,15-23,27,34-35,39H,10-13H2,1-6H3/b14-7+/t15-,16+,17-,18+,19-,20+,21+,22-,23-,27+,28+,29+,30-,31+,32+,33+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C33H42O14
Molecular Weight	662.68
AlogP	-1.42
Hydrogen Bond Acceptor	14.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	8.0
Polar Surface Area	189.04
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	47.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Athelia rolfsii assessed as mycelial growth inhibition	Athelia rolfsii	76.2 ppm
Fungicidal activity against Rhizoctonia solani assessed as mycelial growth inhibition	Rhizoctonia solani	85.9 ppm
Nematicidal activity against fourth-stage juvenile of Rotylenchulus reniformis (reniform nematode) assessed as juvenile immobility after 72 hr by stereoscopic binocular microscopic analysis	Rotylenchulus reniformis	96.6 ppm
Nematicidal activity against Caenorhabditis elegans assessed as mortality at 200 ppm after 24 hr	Caenorhabditis elegans	64.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL451665
FDA SRS	X5T1RMZ28I
PubChem	21725521

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).